Posted by psychobot5000 on November 14, 2011, at 11:53:23
In reply to Re: Triple reuptake inhibitor GSK372475 fails., posted by europerep on November 11, 2011, at 14:08:54
> Is there any reason to believe that a TRI is actually more effective than a combination of, say, venlafaxine and bupropion?
>
> Ok, I get it, combining agents may produce synergistic side effects and having to take several different meds decreases patient compliance, so I probably shouldn't bash those agents, but still... I don't think TRIs have a significantly greater antidepressant potential than the combination of agents that add up to triple reuptake inhibition.
>
> I don't think the solution for treatment-resistant depression lies in drugs like vilazodone or TRIs. They may be more tolerable for those remit on "old" monoaminergic drugs, which is great, but they won't make the number of TRD patients go down a lot.I'm forced to agree--though I would note that TRIs would partly deal with the deficiency in drugs affecting dopamine pathways (bupropion, if I remember right, has only modest overall effects, and the stimulants aren't really a fabulous substitute), overall they're not really very innovative drugs. I guess the opposing view hopes that, by sustained action on all three monoamine systems, you'd have a modestly stronger effect, but, sadly, I'm guessing we'll need to look elsewhere, anyway.
In my (extensive, though individual) experience, the S/E of drugs that substantially inhibit the reuptake of noradrenaline or serotonin are not really very tolerable anyway.
poster:psychobot5000
thread:1002099
URL: http://www.dr-bob.org/babble/20111110/msgs/1002527.html